Key result
Transgenic over-expression of cardiac α-actin in ACTC(Co)/KO mice resulted in 20 to 25% less myofibre force production and lower stiffness compared with age-matched wild-types.
The presence of cardiac α-actin instead of skeletal muscle α-actin alters actin conformational changes and lowers myofibre force production, which has implications for designing gene therapies for ACTA1-based congenital myopathies.
Answers are grounded in this paper and cite their sources.
Supports isoform effects on myofibre mechanics in mice; leaves open relevance to ACTA1 gene therapy design.
Multiple congenital myopathies, including nemaline myopathy, can arise due to mutations in the ACTA1 gene encoding skeletal muscle α-actin. The main characteristics of ACTA1 null mutations (absence of skeletal muscle α-actin) are generalized skeletal muscle weakness and premature death. A mouse model (ACTC(Co)/KO) mimicking these conditions has successfully been rescued by transgenic over-expression of cardiac α-actin in skeletal muscles using the ACTC gene. Nevertheless, myofibres from ACTC(Co)/KO animals generate less force than normal myofibres (-20 to 25%). To understand the underlying mechanisms, here we have undertaken a detailed functional study of myofibres from ACTC(Co)/KO rodents. Mechanical and X-ray diffraction pattern analyses of single membrane-permeabilized myofibres showed, upon maximal Ca(2+) activation and under rigor conditions, lower stiffness and disrupted actin-layer line reflections in ACTC(Co)/KO when compared with age-matched wild-types. These results demonstrate that in ACTC(Co)/KO myofibres, the presence of cardiac α-actin instead of skeletal muscle α-actin alters actin conformational changes upon activation. This later finely modulates the strain of individual actomyosin interactions and overall lowers myofibre force production. Taken together, the present findings provide novel primordial information about actin isoforms, their functional differences and have to be considered when designing gene therapies for ACTA1-based congenital myopathies.
No takes yet. Share an insight, caveat, or question.
Ochala et al. (2013) studied Congenital myopathies (ACTA1 null mutations). Transgenic over-expression of cardiac α-actin vs. Age-matched wild-types was evaluated on Myofibre force production and stiffness. Transgenic over-expression of cardiac α-actin in ACTC(Co)/KO mice resulted in 20 to 25% less myofibre force production and lower stiffness compared with age-matched wild-types.
Synapse has enriched 10 related papers. Consider them for comparative context: